News
Filter
-
LifeArc invests in Maxion Therapeutics Series A
-
Reflecting on our commitment to involve patients and the public in our work
-
Reflections from the LifeArc Translational Science Summit on MND and Rare Dementias
-
LifeArc Ventures 2024: new investments, targeted follow-ons and substantive portfolio progress
-
LifeArc and Neuropeutics Inc join forces to advance a new treatment for MND/ALS
-
New AI tool aims to detect early signs of dementia during routine eye tests
-
LifeArc and Cleveland Clinic join forces to develop new monoclonal antibody therapeutics for patients with high unmet medical needs
-
Third global Longitude Prize to be launched in 2025 focusing on ALS
-
LifeArc appoints Chief Medical Officer to deliver more scientific breakthroughs for patients
-
Clare Terlouw, Head of LifeArc Ventures, talks to In Vivo’s Ashley Yeo on the improving investment climate
-
£2.7m infectious disease fund to boost rapid testing, drug trials and innovative specimen storage
-
LifeArc Ventures invests in Fluid Biomed
